Trilipix (fenofibric acid) is a lipid regulating agent available as delayed release capsules for oral administration. Each delayed release capsule contains choline fenofibrate, equivalent to 45 mg or 135 mg of fenofibric acid.
Co-administration Therapy with Statins for the Treatment of Mixed Dyslipidemia
Trilipix is indicated as an adjunct to diet in combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal.
CHD risk equivalents comprise:
Treatment of Severe Hypertriglyceridemia
Other clinical forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and symptomatic carotid artery disease);
Multiple risk factors that confer a 10-year risk for CHD > 20%
Trilipix is indicated as adjunctive therapy to diet to reduce TG in patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacological intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of Trilipix therapy on reducing this risk has not been adequately studied.
Treatment of Primary Hyperlipidemia or Mixed Dyslipidemia
Trilipix is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia.
Important Limitations of Use
No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established.
General Considerations for Treatment
Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus.
Laboratory studies should be performed to establish that lipid levels are abnormal before instituting Trilipix therapy.
Every reasonable attempt should be made to control serum lipids with non-drug methods including appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that may be contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (beta-blockers, thiazides, estrogens) should be discontinued or changed if possible, and excessive alcohol intake should be addressed before triglyceride-lowering drug therapy is considered. If the decision is made to use lipid-altering drugs, the patient should be instructed that this does not reduce the importance of adhering to diet.
Drug therapy is not indicated for patients who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL.
Media Articles Related to Trilipix (Fenofibrate)
Fenofibrate Works as Well in Women With Diabetes as in Men
Source: theheart.org | Medscape Cardiology Headlines [2014.08.18]
Fenofibrate appears to work as well in women with type 2 diabetes as in men, according to a new FIELD analysis, providing reassurance after the ACCORD Lipid trial.
Medscape Medical News
Heart and stroke risks in diabetic women reduced 30 percent by cholesterol drug
Source: Diabetes News From Medical News Today [2014.08.20]
The cholesterol-lowering drug fenofibrate cuts cardiovascular disease risks by 30 per cent in women with type-2 diabetes, a new University of Sydney study reveals.
Fibrate Seems to Reduce CVD Risk in Diabetic Women
Source: MedPage Today Endocrinology [2014.08.19]
(MedPage Today) -- Contrary to earlier results, fenofibrate may actually lower cardiovascular risk in women with type 2 diabetes, researchers found.
Published Studies Related to Trilipix (Fenofibrate)
Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. [2011.11]
OBJECTIVE: To assess the long-term safety and efficacy of a fenofibrate/pravastatin 160/40 mg fixed-dose combination in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy... CONCLUSIONS: Long-term co-administration of fenofibrate/pravastatin 160/40 mg in a single capsule was well tolerated and produced complementary benefits on the overall lipid profile of high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg.
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. [2011.08.01]
Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-alpha... In conclusion, monotherapy with fenofibrate remains a useful option in patients with dyslipidemia, particularly in atherogenic dyslipidemia characterized by high TG and low HDL-C levels.
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. [2011.07]
CONTEXT: HIV patients on antiretroviral therapy (ART) have a unique dyslipidemia [elevated triglycerides and non-high-density lipoprotein-cholesterol (HDL-C), low HDL-C] with insulin resistance (characterized by hypoadiponectinemia). OBJECTIVE: The aim was to test a targeted, comprehensive, additive approach to treating the dyslipidemia... CONCLUSIONS: A combination of fenofibrate and niacin with low-saturated-fat D/E is effective and safe in increasing HDL-C, decreasing non-HDL-C and hypertriglyceridemia, and ameliorating hypoadiponectinemia in patients with HIV/ART-associated dyslipidemia.
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials. [2011.06]
BACKGROUND: Fenofibrate is used to treat primary hypercholesterolemia, mixed lipidemia, and hypertriglyceridemia in adults who do not respond to nonpharmacologic measures. Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety. A new orally administered agent, fenofibric acid, was developed as an alternative to fenofibrate. OBJECTIVE: Two separate studies were conducted to evaluate the bioequivalence of fenofibric acid relative to fenofibrate under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of fenofibric acid... CONCLUSIONS: In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg fenofibric acid met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg fenofibrate tablets with respect to the rate and extent of fenofibric acid absorption in both fed and fasted states. Fenofibric acid at the dose studied was well tolerated in this population. Copyright (c) 2011 Elsevier HS Journals, Inc. All rights reserved.
High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. [2011.06]
The aim of the study was to compare the efficacy of high-dose rosuvastatin, low-dose rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega-3 fatty acids with regard to the lipid profile in patients with mixed hyperlipidemia. The primary endpoint was changes in non-high density lipoprotein-cholesterol (non-HDL-C) levels...
Clinical Trials Related to Trilipix (Fenofibrate)
Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL) Physicochemical and Functional Characteristics in Patients With Coronary Heart Disease [Recruiting]
Fenofibrate is a drug that acts on the PPAR alpha receptors, increasing HDL-cholesterol and
decreasing triglyceride levels. The interaction with these receptors has antiatherogenic
actions by regulating the expression con key proteins that participate in vascular
inflammation, plaque stability and thrombosis.
Fenofibrate reduces triglycerides and increases HDL-C in plasma. It also decreases small,
dense LDL particles. The use of this drug has resulted in improvement of vascular function
measured by endothelial function. Our hypotheses state that fenofibrate will improve:
endothelial function, improve HDL antioxidant capacity and size distribution towards a
predominance of small HDL particles.
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza� in Patients With Severe Hypertriglyceridemia [Recruiting]
A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic [Recruiting]
Atherogenic dyslipidemia includes patients who have coronary heart disease (CHD) or CHD risk
equivalents, whose TG level is not adequately controlled after statin monotherapy. According
to the recent published EAS consensus, fibrate is suggested to be added to this type of
patient who has insufficient improvement. The purpose of the study is to evaluate the
efficacy on lipid control and the safety of adding fenofibrate in patients on a background
of statin treatment.
Predictors of Response to Fenofibrate [Recruiting]
Fenofibrate is one of the best options for treating hypertriglyceridemia. In the majority of
patients, fenofibrate lowers triglycerides (TG) by 24-55% and improves HDL- and
LDL-cholesterol. However, the response to fenofibrate is highly variable and currently there
are no screening tests to identify poor responders. Genetic and environmental factors may
explain the high variability in response. Although exploratory in nature, this study is of
clinical and public health importance because prediction of drug response among those with
hypertriglyceridemia is clinically challenging and fenofibrate prescription costs are large
($90 to $130/patient/month); targeting the responsive patients at the outset will help
improve treatment outcomes at a lower cost. If successful, the investigators will propose to
conduct a large, randomized trial on the effect of pre-prescription genotyping on
A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume [Not yet recruiting]
The purpose of this study is to evaluate the potential benefits of Fenofibrate in 300 adults
with Type 1 diabetes mellitus who are at high risk of eye damage.
Reports of Suspected Trilipix (Fenofibrate) Side Effects
Blood Triglycerides Increased (8),
Upper Respiratory Tract Infection (8),
Muscle Spasms (7),
Muscular Weakness (7),
Hepatic Enzyme Increased (6),
Drug Dose Omission (5),
Diabetes Mellitus (5), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Trilipix has an overall score of 8. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Trilipix review by 48 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || high ldl|
|Dosage & duration:|| || 135 mg taken once per day for the period of 4 months|
|Other conditions:|| || low t, low thyroid|
|Other drugs taken:|| || levoxyl, clomid|
|Benefits:|| || Quickly lowered ldl 100 points.|
|Side effects:|| || knee tenderness|
|Comments:|| || blood tests done 2 months after initial use showed dramatic drop in ldl and small particles. Its unknown what synergistic effect , if any can be attributed to Clomid for low T and levoxyl for low thyroid function, which were prescribed at the same time as the trilipix.. Both Testosterone and thyroid function were normalized simultaneously with ldl reduction. No severe side effects have been noticed from any of the drugs.|
Page last updated: 2014-08-20